chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 55.0
Sex: M
Vaccine: COVID19
Symptoms: Pain, Pyrexia
Clinical narrative: Exhausted; Body aches; Coughing; Fever; chills; Congestion; Chest pain; This is a spontaneous report from a contactable consumer, the patient. A 55-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EW0150) via an unspecified route of administration in the left arm on 26Apr2021 at 14:00 (at the age of 55-years-old) as a single dose for COVID-19 immunisation. Medical history included blood pressure high and kidney disease. The patient had no known allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included paracetamol (TYLENOL), benzalkonium chloride, sodium chloride (ALIVE), dextromethorphan hydrobromide, guaifenesin, paracetamol, pseudoephedrine hydrochloride (DAYQUIL) and dextromethorphan hydrobromide, doxylamine succinate, ephedrine sulfate, ethanol, paracetamol (NYQUIL); all for an unknown indication from an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EXT5318) via an unspecified route of administration in the left arm on 05Apr2021 (at the age of 55-years-old) as a single dose for COVID-19 immunisation. On 26Apr2021 at 15:00, the patient experienced exhausted, body aches, coughing, fever, chills, congestion and chest pain. Since the day the patient got the vaccine he had the symptoms at the time of this report. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events exhausted, body aches, coughing, fever, chills, congestion and chest pain was not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Confusional state, Dizziness, Dysgeusia, Fatigue, Feeling hot
Clinical narrative: Headache; Metallic taste; Fever; Confusion; Muscle pain; Unusual organ pain; Hot feet; Dizziness; Fatigue; hot hands; This is a spontaneous report from a contactable consumer, the patient. A 49-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EAU206) via an unspecified route of administration in the right arm on 30Apr2021 at 10:15 (at the age of 49-years-old) as a single dose for COVID-19 immunisation. Medical history included fruit allergy (ligonberries). Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included cetirizine hydrochloride (ZYRTEC), estradiol (ESTROGEN) and progesterone (MANUFACTURER UNKNOWN); all for unknown indication, from an unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 30Apr2021 at 10:15, the patient experienced headache, metallic taste, fever, confusion, muscle pain, unusual organ pain, hot feet and hands, dizziness and fatigue. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of adverse events.  Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events headache, metallic taste, fever, confusion, muscle pain, unusual organ pain, hot feet and hands, dizziness and fatigue were resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Myalgia, Pain, Pyrexia
Clinical narrative: Headache; Metallic taste; Fever; Confusion; Muscle pain; Unusual organ pain; Hot feet; Dizziness; Fatigue; hot hands; This is a spontaneous report from a contactable consumer, the patient. A 49-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EAU206) via an unspecified route of administration in the right arm on 30Apr2021 at 10:15 (at the age of 49-years-old) as a single dose for COVID-19 immunisation. Medical history included fruit allergy (ligonberries). Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included cetirizine hydrochloride (ZYRTEC), estradiol (ESTROGEN) and progesterone (MANUFACTURER UNKNOWN); all for unknown indication, from an unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 30Apr2021 at 10:15, the patient experienced headache, metallic taste, fever, confusion, muscle pain, unusual organ pain, hot feet and hands, dizziness and fatigue. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of adverse events.  Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events headache, metallic taste, fever, confusion, muscle pain, unusual organ pain, hot feet and hands, dizziness and fatigue were resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 66.0
Sex: F
Vaccine: COVID19, UNK
Symptoms: Neutrophil count decreased, Platelet count decreased
Clinical narrative: Platelets were down to something like 70 and my neutrophils were 400. This last time my platelets were 123 And my neutrophils were 1200; Platelets were down to something like 70 and my neutrophils were 400. This last time my platelets were 123 And my neutrophils were 1200; This is a spontaneous report received from Pfizer. This contactable consumer (patient) reported to pharmacy about herself that:  A 66-years-old female patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Batch/Lot number: unknown), via an unspecified route of administration on Feb2021 (age at vaccination was 66 years) as dose 2, single for COVID-19 immunization and palbociclib (IBRANCE, Batch/Lot number: unknown, Expiration date: 30Jun2022), oral from an unspecified date, at 100 mg oral daily (Daily for 21 days) for breast cancer. Patient medical history of allergies: acetaminophen, codeine, enoxaparin, hydrocodone, lovenox, oxycodone. Concomitant medication(s) included calcium carbonate (CALCIUM CARBONATE), docusate sodium (COLACE), lorazepam (LORAZEPAM), eszopiclone (LUNESTA), omeprazole (OMEPRAZOLE), ondansetron (ONDANSETRON), oxycodone hcl (OXYCODONE HCL),levothyroxinesodium(SYNTHROID),hydrochlorothiazide,valsartan(VALSARTAN/HIDROCLOROTIAZIDA). The patient previously received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Batch/Lot number: unknown, Expiration date: unknown) via an unspecified route of administration on Jan2021 as dose 1, single for COVID-19 immunization. The patient received COVID shot in Jan and February and my blood work went kinda wonky afterwards, so skip a month. Platelets were down to something like 70 and neutrophils were 400. Last platelets were 123 and neutrophils were 12000. Patient haven't had any problems for 4 years the only thing different was patient got COVID shot. Patient started back on Ibrance on 23April2021 after being off for 5 weeks per pt. The patient underwent lab tests and procedures which included neutrophil count decreased which showed 400 result and platelet count decreased which showed 70 results on an unspecified date. The outcome of the events was unknown.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 17.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Dizziness, Heart rate increased, Pain, Pyrexia
Clinical narrative: Low grade fever of 100.4; Severe body aches; Dizziness; Rapid heart rate; Rapid breathing rate; Soreness at injection site; This is a spontaneous report from a contactable consumer, the patient. A 17-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0167) via an unspecified route of administration in the left arm on 02May2021 at 16:00 (at the age of 17-years-old) as a single dose for COVID-19 immunisation. The patient did not have any medical history. The patient had no known allergies. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included isotretinoin (CLARAVIS) for an unknown indication from an unknown date and unknown if ongoing. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0158) via an unspecified route of administration in the left arm on 10Apr2021 at 16:00 (at the age of 17-years-old) as a single dose for COVID-19 immunisation. On 03May2021 at 16:00, the patient experienced low grade fever of 100.4 (units unspecified), severe body aches, dizziness, rapid heart rate, rapid breathing rate, soreness at injection site. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. It was unknown whether therapeutic measures were taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events low grade fever of 100.4 (units unspecified), severe body aches, dizziness, rapid heart rate, rapid breathing rate, soreness at injection site were not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 17.0
Sex: F
Vaccine: COVID19
Symptoms: Respiratory rate increased, Vaccination site pain
Clinical narrative: Low grade fever of 100.4; Severe body aches; Dizziness; Rapid heart rate; Rapid breathing rate; Soreness at injection site; This is a spontaneous report from a contactable consumer, the patient. A 17-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0167) via an unspecified route of administration in the left arm on 02May2021 at 16:00 (at the age of 17-years-old) as a single dose for COVID-19 immunisation. The patient did not have any medical history. The patient had no known allergies. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included isotretinoin (CLARAVIS) for an unknown indication from an unknown date and unknown if ongoing. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0158) via an unspecified route of administration in the left arm on 10Apr2021 at 16:00 (at the age of 17-years-old) as a single dose for COVID-19 immunisation. On 03May2021 at 16:00, the patient experienced low grade fever of 100.4 (units unspecified), severe body aches, dizziness, rapid heart rate, rapid breathing rate, soreness at injection site. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. It was unknown whether therapeutic measures were taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events low grade fever of 100.4 (units unspecified), severe body aches, dizziness, rapid heart rate, rapid breathing rate, soreness at injection site were not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Chills, Headache, Pyrexia
Clinical narrative: Chills; Fever (highest reading 102.6); Headache; This is a spontaneous report from a contactable consumer, the patient. A 60-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0171) via an unspecified route of administration in the left arm on 30Apr2021 at 13:00 (at the age of 60-years-old) as a single dose for COVID-19 immunisation. Medical history includes asthma, eczema, thyroid cancer survivor, breast cancer survivor and allergy to penicillin. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Concomitant medications included lisinopril (MANUFACTURER UNKNOWN), levothyroxine (MANUFACTURER UNKNOWN), anastrozole (MANUFACTURER UNKNOWN) and meloxicam (MANUFACTURER UNKNOWN); all for an unknown indication from an unknown date and unknown if ongoing. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7533) via an unspecified route of administration in left arm on 02Apr2021 at 13:00 as a single dose for COVID-19 immunisation. On 01May2021 at 02:45, the patient experienced that chills, fever (highest reading 102.6), headache, started 12 hours after second dose of vaccine and lasted 30 hours. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were taken as a result of the events which included treatment with extra strength paracetamol (Tylenol) for every 6 hours. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events chills, fever and headache were resolved on 02May2021 at 08:45, after the duration of 30 hours.  No follow-up attempts are needed. No further information is expected.
Age: 60.0
Sex: M
Vaccine: COVID19
Symptoms: Pyrexia, Vaccination site pain
Clinical narrative: Fever; Pain at injection site; This is a spontaneous report from a contactable consumer. A 60-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an intramuscular route of administration in the right arm on 22Apr2021 at 14:30 (at the age of 60-years-old) as a single dose for COVID-19 immunisation. The medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The concomitant medications was not reported. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an intramuscular route of administration in the right arm on 01Apr2021 at 14:30 (at the age of 60-years-old) as a single dose for COVID-19 immunisation. On 22Apr2021 at 23:45, the patient experienced fever and pain at injection site. The adverse events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. The patient did not receive any treatment for the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events fever and pain at injection site were resolved on an unspecified date in Apr2021.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 26.0
Sex: F
Vaccine: COVID19
Symptoms: Paraesthesia
Clinical narrative: Pins and needles feeling in hands after the second shot. It got worse and spread to all over my body by Wednesday; This is a spontaneous report from a contactable consumer, the patient. A 26-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0164) via an unspecified route of administration in the left arm on 17Apr2021 at 12:30 (at the age of 26-year-old), as a single dose for COVID-19 immunisation. Medical history included known allergy to sulfa drugs. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Concomitant medications included fexofenadine hydrochloride (ALLEGRA), fluticasone propionate (FLONASE) and melatonin (MANUFACTURER UNKNOWN) and unspecified multivitamin; all for unknown indications from unknown date and unknown if ongoing. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8732) via an unspecified route of administration in the left arm on 27Mar2021 at 15:30 (at the age of 26-year-old), as a single dose for COVID-19 immunisation. On 19Apr2021, after the second shot, the patient experienced pins and needles feeling in hands. It got worse and spread to all over her body by wednesday and was gone by sunday. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event pins and needles was resolved on an 25Apr2021, by Sunday.   No follow-up attempts are needed. No further information is expected.
Age: 41.0
Sex: M
Vaccine: COVID19
Symptoms: Feeling abnormal, Pyrexia, Vaccination site pain
Clinical narrative: Fever; Site injection pain,; Felt terrible; This is a spontaneous report from a non-contactable consumer. A 41-year-old male patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 21Apr2021 (at the age of 41-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive concomitant medications. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 31Mar2021 (at the age of 41-years-old) as a single dose for COVID-19 immunisation. On 21Apr2021, the patient experienced fever, site injection pain and felt terrible for about 24-48 hours post injection. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events fever, site injection pain and felt terrible was resolved on an unknown date in Apr2021.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 44.0
Sex: F
Vaccine: COVID19
Symptoms: Feeling jittery, Headache, Hypoaesthesia, Musculoskeletal stiffness, Pyrexia
Clinical narrative: Stiff and numbness on facial area, mostly nose, above upper lip and between eyebrows. Blurred vision, headache, jittery, low grade fever.; Stiff and numbness on facial area, mostly nose, above upper lip and between eyebrows; Blurred vision; Headache; Jittery; Low grade fever; This is a spontaneous report from a contactable consumer, the patient. A 44-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0164) via an unspecified route of administration in the left arm on 17Apr2021 (at the age of 44-year-old) as a single dose for COVID-19 immunisation. Medical history included anxiety, depression and allergy to sulfa. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included piroxicam (PAXIL) from unknown date for unspecified indication and unknown if ongoing. On 17Apr2021, the patient experienced stiff and numbness on facial area, mostly nose, above upper lip and between eyebrow, blurred vision, headache, jittery and low grade fever. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events, stiff and numbness on facial area, mostly nose, above upper lip and between eyebrows, blurred vision, headache, jittery and low grade fever was resolved on an unknown date on Apr2021.   No follow-up attempts are needed. No further information is expected.
Age: 44.0
Sex: F
Vaccine: COVID19
Symptoms: Vision blurred
Clinical narrative: Stiff and numbness on facial area, mostly nose, above upper lip and between eyebrows. Blurred vision, headache, jittery, low grade fever.; Stiff and numbness on facial area, mostly nose, above upper lip and between eyebrows; Blurred vision; Headache; Jittery; Low grade fever; This is a spontaneous report from a contactable consumer, the patient. A 44-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0164) via an unspecified route of administration in the left arm on 17Apr2021 (at the age of 44-year-old) as a single dose for COVID-19 immunisation. Medical history included anxiety, depression and allergy to sulfa. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included piroxicam (PAXIL) from unknown date for unspecified indication and unknown if ongoing. On 17Apr2021, the patient experienced stiff and numbness on facial area, mostly nose, above upper lip and between eyebrow, blurred vision, headache, jittery and low grade fever. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events, stiff and numbness on facial area, mostly nose, above upper lip and between eyebrows, blurred vision, headache, jittery and low grade fever was resolved on an unknown date on Apr2021.   No follow-up attempts are needed. No further information is expected.
Age: 33.0
Sex: F
Vaccine: COVID19
Symptoms: Bedridden, Fatigue, Nausea
Clinical narrative: Fatigue; Feeling like "I" will throw up; Unable to get out of bed; This is a spontaneous report from a contactable consumer, the patient. A 33-year-old female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 24Apr2021 at 10:00 (at the age of 33-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. It was unknown whether the patient was pregnant at the time of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any concomitant medications. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 27Apr2021, the patient experienced fatigue, was unable to get out of bed and felt like she would throw up. It was unknown whether any therapeutic measures were taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events fatigue, unable to get out of bed and felt like she would throw up were unknown at the time of this report.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site discolouration, Vaccination site swelling, Vaccination site warmth
Clinical narrative: Severe swelling of arm about 2 inches from injection site/ raised skin 3 days after dose; Severe swelling of arm about 2 inches from injection site. Very hot to the touch and purple/red in color; Severe swelling of arm about 2 inches from injection site. Very hot to the touch; This is a spontaneous report from a non-contactable consumer, the patient. A 32-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8733) via an unspecified route of administration on an unknown date as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Concomitant medications were not reported. On an unknown date, the patient experienced severe swelling of arm about 2 inches from injection site. On an unknown date, 3 days after vaccination, the patient experienced very hot to the touch and purple/red in color and raised skin. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events severe swelling of arm about 2 inches from injection site/ raised skin 3 days after dose, very hot to the touch and purple/red in color were unknown at the time of this report.  No follow-up attempts are possible. No further information is expected.
Age: 33.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Nausea, Pain, Pyrexia
Clinical narrative: Nausea; Body aches; Headaches; Low fever; This is a spontaneous report from a contactable consumer (patient). A 33-year-old non pregnant female patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: EL3247), intramuscular, administered in Arm Left on 26Apr2021 09:00 (at the age of 33-year-old) as single dose for COVID-19 immunization. The patient had no medical history. The patient's concomitant medications were not reported. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient previously received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: EL3247), intramuscular, administered in Arm Left on 05Apr2021 09:00 (at the age of 33-year-old) as single dose for COVID-19 immunization. Prior to vaccination, the patient was not diagnosed with COVID-19. On 26Apr2021 18.30, the patient experienced nausea, body aches, and headaches, with low fever. The patient did not receive any treatment for the events. Since the vaccination, the patient had not been tested for COVID-19. Outcome of the events was recovering.  No follow-up attempts are needed. No further information is expected.
Age: 46.0
Sex: F
Vaccine: COVID19
Symptoms: Eye pain, Headache
Clinical narrative: Constant nagging headache on the left side of the head; Pain in the back of the eye since getting the vaccine; This is a spontaneous report from a contactable consumer, the patient. A 46-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8731) via an unspecified route of administration in the left arm on 15Apr2021 at 10:30 (at the age of 46-years-old) as a single dose for COVID-19 immunisation. Medical history included palpitations and tachycardia. It was unknown whether the patient had any allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included metoprolol (MANUFACTURER UNKNOWN), flecainide (MANUFACTURER UNKNOWN), biotin (MANUFACTURER UNKNOWN), vitamin d nos (VITAMIN D) and tocopherol (VITAMIN E), all for an unknown indication from an unknown date and unknown if ongoing. The patient did not receive any other vaccine within four weeks prior to the COVID-19 vaccine. On 15Apr2021 at 12:00, the patient experienced constant nagging headache on the left side of the head and pain in the back of the eye since getting the vaccine. Headaches might subside, but came back more often and more aggressive. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. No therapeutic measures were not taken as a result of reported events. The clinical outcome of the events headache on the left side of the head and pain in the back of the eye was not recovered at the time of the report.  No follow-up attempts are needed. No further information is expected.
Age: 55.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Feeling abnormal, Muscle fatigue, Urticaria, Vaccination site pain
Clinical narrative: The next day "I" had muscle fatigue in arms and legs; About 2 hours after shot "I" experienced light hives on face (eyelids/lips) and palms of hands; "I" felt light headed, fuzzy immediately after the shot.; "I" felt light headed, fuzzy immediately after the shot.; Injection site pain and slight swelling for a few days which was not unnexpected.; Injection site pain and slight swelling for a few days which was not unnexpected.; This is a spontaneous report from a contactable consumer, the patient. A 55-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0150) via an unspecified route of administration in the left arm on 12Apr2021 at 11:30 (at the age of 55-years-old) as a single dose for COVID-19 immunisation. The medical history included allergy to some antibiotics like penicillin and acidic foods. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any medications within two weeks of vaccination. The patient previously took acetylsalicylic acid (ASPIRIN), codeine (MANUFACTURER UNKNOWN), dextromethorphan hydrobromide/doxylamine succinate/ephedrine sulfate/ethanol/paracetamol (NYQUIL) on unknown dates and experienced allergy. On 12Apr2021 at 11:30, immediately after the shot the patient felt light headed and fuzzy. The patient waited in room for 30 minutes and then in lobby for another 30 on her own. On 12Apr2021 at 13:30, about 2 hours after shot, the patient experienced light hives on face (eyelids/lips) and palms of hands. On 13Apr2021, the next day, the patient had muscle fatigue in arms and legs and on an unknown date in Apr2021 injection site pain and slight swelling for few days which was not unexpected. The adverse events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events light headed, fuzzy, light hives on face (eyelids/lips) and palms of hands, muscle fatigue in arms and legs, injection site pain and slight swelling was resolved on an unknown date in Apr2021.    No follow-up attempts are needed. No further information is expected.
Age: 55.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site swelling
Clinical narrative: The next day "I" had muscle fatigue in arms and legs; About 2 hours after shot "I" experienced light hives on face (eyelids/lips) and palms of hands; "I" felt light headed, fuzzy immediately after the shot.; "I" felt light headed, fuzzy immediately after the shot.; Injection site pain and slight swelling for a few days which was not unnexpected.; Injection site pain and slight swelling for a few days which was not unnexpected.; This is a spontaneous report from a contactable consumer, the patient. A 55-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0150) via an unspecified route of administration in the left arm on 12Apr2021 at 11:30 (at the age of 55-years-old) as a single dose for COVID-19 immunisation. The medical history included allergy to some antibiotics like penicillin and acidic foods. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any medications within two weeks of vaccination. The patient previously took acetylsalicylic acid (ASPIRIN), codeine (MANUFACTURER UNKNOWN), dextromethorphan hydrobromide/doxylamine succinate/ephedrine sulfate/ethanol/paracetamol (NYQUIL) on unknown dates and experienced allergy. On 12Apr2021 at 11:30, immediately after the shot the patient felt light headed and fuzzy. The patient waited in room for 30 minutes and then in lobby for another 30 on her own. On 12Apr2021 at 13:30, about 2 hours after shot, the patient experienced light hives on face (eyelids/lips) and palms of hands. On 13Apr2021, the next day, the patient had muscle fatigue in arms and legs and on an unknown date in Apr2021 injection site pain and slight swelling for few days which was not unexpected. The adverse events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events light headed, fuzzy, light hives on face (eyelids/lips) and palms of hands, muscle fatigue in arms and legs, injection site pain and slight swelling was resolved on an unknown date in Apr2021.    No follow-up attempts are needed. No further information is expected.
Age: 55.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia, Myalgia, Pain, Pain in extremity, Salivary hypersecretion
Clinical narrative: Excessive saliva - so much so that I "spit" when I talk (occasionally); Pains in hands; Pain in shoulder, pain in joints; Aching; Soar muscles; This is a spontaneous report from a contactable consumer, the patient. A 55-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 03Apr2021 at 12:00 (at the age of 55-years-old) as a single dose for COVID-19 immunisation. Medical history included bariatric surgery in 2018, penicillin allergy and COVID-19. Prior to the vaccination, the patient was diagnosed with COVID-19. Concomitant medications taken within two weeks of vaccination included levothyroxine sodium (SYNTHROID) for unknown indication on unknown date and unknown if ongoing. The patient previously took omeprazole (PRILOSEC) and experienced drug allergy. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 17Apr2021, the patient experienced excessive salivation, so much so that she spat when she talked occasionally. The patient also had pains in hands and shoulders, aching, sore muscles, pain in joints. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events excessive saliva, so much so that she spat when she talked occasionally; pains in hands and shoulders, aching, sore muscles, pain in joints was unknown at the time of this report.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 41.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Body temperature, Burning sensation, Headache, Pyrexia
Clinical narrative: 104 F fever; Headache; Vertigo; Ears ringing; Open mouth sores (still there after 5 days, hard to eat); Joint pain (hips); Lower legs, burning; This is a spontaneous report from a contactable healthcare professional, the patient. A 41-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0164) via an unspecified route of administration in the left arm on 22Apr2021 at 19:15 (at the age of 41-years-old) as a single dose for COVID-19 immunisation. Medical history included autoimmune premature ovarian failure symptoms. The patient did not have allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included levothyroxine, liothyronine (NP THYROID), taken for an unspecified indication from an unknown date and unknown if ongoing. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8737) via an unspecified route of administration in the left arm on 01Apr2021 at 14:15 (at the age of 41-years-old) as a single dose for COVID-19 immunisation. On 23Apr2021 at 13:30, the patient experienced 104 Fahrenheit fever, headache, vertigo, ears ringing, open mouth sores (was still present after 5 days, hard to eat), joint pain (hips) and lower legs burning. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of the events and included treatment with paracetamol (TYLENOL) 1000mg/ day (2 days). Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events fever, headache, vertigo, ears ringing, open mouth sores (hard to eat), joint pain (hips) and lower legs burning were resolving at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 41.0
Sex: F
Vaccine: COVID19
Symptoms: Stomatitis, Tinnitus, Vertigo
Clinical narrative: 104 F fever; Headache; Vertigo; Ears ringing; Open mouth sores (still there after 5 days, hard to eat); Joint pain (hips); Lower legs, burning; This is a spontaneous report from a contactable healthcare professional, the patient. A 41-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0164) via an unspecified route of administration in the left arm on 22Apr2021 at 19:15 (at the age of 41-years-old) as a single dose for COVID-19 immunisation. Medical history included autoimmune premature ovarian failure symptoms. The patient did not have allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included levothyroxine, liothyronine (NP THYROID), taken for an unspecified indication from an unknown date and unknown if ongoing. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8737) via an unspecified route of administration in the left arm on 01Apr2021 at 14:15 (at the age of 41-years-old) as a single dose for COVID-19 immunisation. On 23Apr2021 at 13:30, the patient experienced 104 Fahrenheit fever, headache, vertigo, ears ringing, open mouth sores (was still present after 5 days, hard to eat), joint pain (hips) and lower legs burning. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of the events and included treatment with paracetamol (TYLENOL) 1000mg/ day (2 days). Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events fever, headache, vertigo, ears ringing, open mouth sores (hard to eat), joint pain (hips) and lower legs burning were resolving at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 57.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Fatigue, Rash
Clinical narrative: 12,13th day, fatigue; 12,13th day joint pain; 10th day following dose 1, rash on back of both arms; This is a spontaneous report from a non-contactable consumer, the patient. A 57-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 14Apr2021 at 16:00 (at the age of 57-years-old) as a single dose for COVID-19 immunisation. The patient had unspecified medical history. The patient had unspecified allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included many supplements (MANUFACTURER UNKNOWN) for unknown indication from unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 24Apr2021 at 16:00, 10th day following dose 1, the patient experienced rash on back of both arms. On 26Apr2021 and 27Apr2021, 12th and 13th day, the patient experienced joint pain and fatigue. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event rash on back of both arms, joint pain, and fatigue was not resolved at the time of this report.  No follow-up attempts are required, information about lot/batch number cannot be obtained. No further information is expected.
Age: 56.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Malaise, Pyrexia
Clinical narrative: Day after vaccine 101.2 temp; Felt sick for about 12 hrs; This is a spontaneous report from a contactable consumer, the patient. A 56-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8735) via an unspecified route of administration in the left arm on 22Apr2021 at 12:45 (at the age of 56-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19 on 07Apr2021. The patient had no known allergies. Prior to the vaccination, the patient was diagnosed with COVID-19 positive on 07Apr2021. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included paracetamol (TYLENOL) and ibuprofen (MANUFACTURER UNKNOWN); both from an unknown date for an unknown indications and unknown if ongoing. On 23Apr2021 at 07:00, day after the vaccine, the patient experienced 101.2 temperature (temp) and felt sick for about 12 hours. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. On 23Apr2021 at 07:00, the patient underwent body temperature test and the result was 101.2 (unspecified units). Therapeutic measures were not taken as a result of the events. The clinical outcome of the events day after vaccine 101.2 temperature was resolved on an unknown date in Apr2021 and the event felt sick for about 12 hours was resolved on 23Apr2021 at 19:00.  No follow-up attempts are needed. No further information is expected.
Age: 61.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Chills, Fatigue, Headache, Myalgia
Clinical narrative: Fatigue; Joint pain; Muscle pain; Chills; Headache; Sore injection site; This is a spontaneous report from a contactable consumer, the patient. A 61-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 25Apr2021 at 16:45 (at the age of 61-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included mirtazapine (MANUFACTURER UNKNOWN), propranolol (MANUFACTURER UNKNOWN) and hydroxyzine hydrochloride (HYDROXIZINE); all from unknown dates for unknown indications and unknown if ongoing. The patient previously received pneumococcal vaccine (MANUFACTURER UNKNOWN) on an unknown date for an unknown indication and experienced allergy to vaccine. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 26Apr2021 at 02:00, the patient experienced fatigue, muscle and joint pain, chills, headache and sore injection site. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events fatigue, muscle and joint pain, chills, headache and sore injection site were resolving at the time of this report.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 61.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: Fatigue; Joint pain; Muscle pain; Chills; Headache; Sore injection site; This is a spontaneous report from a contactable consumer, the patient. A 61-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 25Apr2021 at 16:45 (at the age of 61-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included mirtazapine (MANUFACTURER UNKNOWN), propranolol (MANUFACTURER UNKNOWN) and hydroxyzine hydrochloride (HYDROXIZINE); all from unknown dates for unknown indications and unknown if ongoing. The patient previously received pneumococcal vaccine (MANUFACTURER UNKNOWN) on an unknown date for an unknown indication and experienced allergy to vaccine. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 26Apr2021 at 02:00, the patient experienced fatigue, muscle and joint pain, chills, headache and sore injection site. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events fatigue, muscle and joint pain, chills, headache and sore injection site were resolving at the time of this report.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: Paraesthesia
Clinical narrative: After the dose, I felt pins and needles from my finger tips to my elbow, from my tip of my toes to my knees; This is a spontaneous report from a contactable consumer, the patient. A 62-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8730) via an unspecified route of administration in the left arm on 25Mar2021 at 18:00 (at the age of 62-years-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure under control. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included amlodipine (MANUFACTURER UNKNOWN) and unspecified vitamins; both from an unknown dates for an unknown indications and unknown if ongoing. The patient previously received acetylsalicylic acid (ASPIRIN) and experienced drug allergy. On 25Mar2021 at 18:15, after the dose, the patient experienced pins and needles from finger tips to elbow, from tip of toes to knees. This happened right after the patient had the dosage. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event pins and needles from finger tips to elbow, from tip of toes to knees was resolving at the time of this report.  No follow-up attempts are needed. No further information is expected.